Highlighted Charts
U.S.: Olin Corporation ( OLN ), Trinity Industries ( TRN ), Service Corp ( SCI ), Helen Of Troy Limited ( HELE ) , EQT Corporation ( EQT ), Interactive Brokers Group ( IBKR ), ICU Medical ( ICUI ), Kroger ( KR ), Qurate Retail ( QRTEA ), Advanced Energy ( AEIS ), Hewlett Packard ( HPE ), Logmein ( LOGM ), Alaska Air Group Corporation ( ALK ).
Developed: Israel Chemicals limited ( ICL.IL; ICL IT ), Line ( LINE.JP; 3938 JP ), Kikkoman ( KN@N.JP; 2801 JP ), Caltex Australia ( CTX.AU; CTX AU ), Mizuho Financial Bank ( MIZH.JP; 8411 JP ), Morphosys ( MORX.DE; MOR GR ), Lawson ( LAWS.JP; 2651 JP ), Infineon Technologies ( IFXX.DE; IFX GR ), Trend Micro ( REND.JP; 4704 JP ), Mitsui Osk Lines ( MO@N.JP; 9104 JP ).
Emerging: Koza Altin Isletmeleri ( KAI.TR; KOZAL TI ), Samsung C&T ( CLZ.KR; 028260 KS ), Krung Thai Bank ( KTBT.TH; KTB TB ).
Stocks worth focusing on in this week’s Global Laggards:
U.S.
ICU Medical ( ICUI ) – Health Care; $4.8B market cap— is a pure play in the intravenous (IV) therapy business. The Company makes infusion products and solutions, IV solutions, PCA pumps, and monitoring devices used in hospitals and clinics. ICU earns a majority of its revenue from its infusion consumables segment providing pipes to deliver fluids and medications to patients. ICU Medical is either number one or two in the segments in which they compete. The Company earns nearly 75% of its revenue from the US, though they sell their products in more than 95 countries.
Q4 revenue by segment ( y/y growth ): infusion consumables, 38% ( +1% ); IV solutions, 30% ( -27% ); IV systems, 28% ( 4% ); critical care, 4 % ( 0% )
2018 revenue by segment ( y/y growth ): infusion consumables, 36% ( 8% ); IV solutions, 33% ( -11% ); IV systems, 27% ( -3% ); critical care, 4% ( 7% )
The numbers exclude the contract manufacturing done by ICU for Pfizer, which contributed $72M in 2018 and $19M in Q4.
